Clinical trial · Interventional
A Phase II MULTICENTRE Trial of Needle Based Laser Confocal Endomicroscopy of Cystic and Solid Tumours of the Pancreas
NCT02523170CI-TRIAL-00040946CONCYSTcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A multicentre phase II study to determine the safety and efficacy of EUS-guided nCLE in patients with suspected cystic tumours of the pancreas in whom endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is clinically indicated. Patients will be recruited sequentially to undergo nCLE as part of their routine diagnostic evaluation, followed by standard surveillance. This part of the study will recruit 60 patients.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cystadenoma, Mucinous | Mucinous Cystadenoma | ONTOLOGY_EXACT | 0.98 |
| Intraductal Papillary Mucinous Neoplasm | Pancreatic Intraductal Papillary Mucinous Neoplasm | ALIAS | 0.90 |
| Pancreatic Cyst | — | UNRESOLVED | — |
| Serous Cystadenoma | Serous Cystadenoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AQ-Flex 19 probe (Mauna Kea Technologies, Paris) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- EUS guided nCLE
- description
- For patients with indeterminate cystic lesions of the pancreas, in addition to routine diagnostic investigations, patients participating in the study will undergo needle based confocal laser endomicroscopy (using the AQ-flex 19 probe - Mauna Kea Technologies, Paris France) at the time of their endoscopic ultrasound.
- interventionNames
- Device: AQ-Flex 19 probe (Mauna Kea Technologies, Paris)
Primary outcomes (1)
- measure
- Diagnostic accuracy
- timeFrame
- 3 years
- description
- Assess the diagnostic accuracy of the Cellvizio nCLE system for diagnosing cystic lesions of the pancreas, compared to standard diagnostic modalities
Secondary outcomes (3)
- measure
- Adverse events
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. A diagnosis of a pancreatic cystic tumour based on multidisciplinary review of imaging for which EUS-FNA is indicated. 2. Pancreatic cystic tumour \>1cm in size. 3. ECOG performance status 0, 1 or 2. 4. Estimated life expectancy of at least 12 weeks. 5. Age \>18 years. 6. Capable of giving written informed consent. 7. Has not has pancreatitis within the previous 3 months. 8. Women of child-bearing potential must have a negative pregnancy test in the week before nCLE, AND be using an adequate contraception method, which must be continued for at least 1 week after nCLE. Exclusion Criteria: 1. Acute pancreatitis in the last 3 months. 2. Subject with multiple cysts 3. Subjects for whom EUS-FNA or surgery are contraindicated 4. Known allergy to fluorescein dye 5. Any evidence of severe or uncontrolled systemic diseases or laboratory finding that in the view of the investigator makes it undesirable for the patient to participate in the trial. 6. Any psychiatric disorder making reliable informed consent impossible. 7. Pregnancy or breast-feeding. 8. ECOG performance status 3 or 4
References
Publications (1)
- BACKGROUNDKeane MG, Wehnert N, Perez-Machado M, Fusai GK, Thorburn D, Oppong KW, Carroll N, Metz AJ, Pereira SP. A prospective trial of CONfocal endomicroscopy in CYSTic lesions of the pancreas: CONCYST-01. Endosc Int Open. 2019 Sep;7(9):E1117-E1122. doi: 10.1055/a-0957-2976. Epub 2019 Aug 29. PMID 31475228